Tag Archives: Ritu Baral
Aptinyx (APTX) Gets a Buy Rating from Cowen & Co.
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Aptinyx (APTX – Research Report) yesterday. The company’s shares closed last Tuesday at $4.30. According to TipRanks.com, Baral is a 5-star analyst with an average return of 12.8% and
Amicus (FOLD) Receives a Buy from Cowen & Co.
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Amicus (FOLD – Research Report) on October 1 and set a price target of $31.00. The company’s shares closed last Friday at $17.17, close to its 52-week high of
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Epizyme (EPZM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals (ACAD – Research Report), Epizyme (EPZM – Research Report) and Kezar Life Sciences (KZR – Research Report) with bullish sentiments.
NGM Biopharmaceuticals (NGM) Gets a Buy Rating from Cowen & Co.
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on NGM Biopharmaceuticals (NGM – Research Report), with a price target of $30.00. The company’s shares closed last Monday at $11.66. According to TipRanks.com, Baral
Cowen & Co. Keeps Their Buy Rating on Avrobio (AVRO)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Avrobio (AVRO – Research Report) yesterday. The company’s shares closed last Monday at $10.08, close to its 52-week low of $9.95. According to TipRanks.com, Baral is a 4-star analyst
Cowen & Co. Keeps a Buy Rating on Albireo Pharma (ALBO)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Albireo Pharma (ALBO – Research Report) yesterday and set a price target of $39.00. The company’s shares closed last Monday at $22.37. According to TipRanks.com, Baral is a 5-star
